NDLI: Interleukin-2 and histamine in combination inhibit tumour growth and angiogenesis in malignant glioma

Content Provider	PubMed Central
Author	Johansson, M. Henriksson, R. Bergenheim, A. T. Koskinen, L-o D.
Copyright Year	2000
Abstract	Biotherapy including interleukin-2 (IL-2) treatment seems to be more effective outside the central nervous system when compared to the effects obtained when the same tumour is located intracerebrally. Recently published studies suggest that reduced activity of NK cells in tumour tissue can be increased by histamine. The present study was designed to determine whether IL-2 and histamine, alone or in combination, can induce anti-tumour effects in an orthotopic rat glioma model. One group of rats was treated with histamine alone (4 mg kg–1s.c. as daily injections from day 6 after intracranial tumour implantation), another group with IL-2 alone as a continuous subcutaneous infusion and a third group with both histamine and IL-2. The animals were sacrificed at day 24 after tumour implantation. IL-2 and histamine in combination significantly reduced tumour growth. The microvessel density was significantly reduced, an effect mainly affecting the small vessels. No obvious alteration in the pattern of VEGF mRNA expression was evident and no significant changes in apoptosis were observed. Neither IL-2 nor histamine alone caused any detectable effects on tumour growth. Histamine caused an early and pronounced decline in tumour blood flow compared to normal brain. The results indicate that the novel combination of IL-2 and histamine can be of value in reducing intracerebral tumour growth and, thus, it might be of interest to re-evaluate the therapeutic potential of biotherapy in malignant glioma. © 2000 Cancer Research Campaign
Related Links	http://dx.doi.org/10.1054/bjoc.2000.1354
Ending Page	832
Page Count	7
Starting Page	826
File Format	PDF
ISSN	00070920
e-ISSN	15321827
Journal	British Journal of Cancer
Issue Number	6
Volume Number	83
Language	English
Publisher	Nature Publishing Group
Publisher Date	2000-09-01
Access Restriction	Open
Rights Holder	Nature Publishing Group
Subject Keyword	Cancer Research Oncology Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Cancer Research Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Interleukin-2 and histamine in combination inhibit tumour growth and angiogenesis in malignant glioma

Growth of cultured human glioma tumour cells can be regulated with histamine and histamine antagonists.

Alloimmune cells consume interleukin-2 and competitively inhibit the anti-tumour effects of interleukin-2.

Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour–stroma interaction

Alloimmune cells consume interleukin-2 and competitively inhibit the anti-tumour effects of interleukin-2

Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma

Tumour cell products inhibit both functional and immunoreactive interleukin 2 production by human blood lymphocytes.

Nitrosoureas Inhibit the Stathmin Mediated Migration and Invasion of Malignant Glioma Cells

Histamine Formation and Tumour Growth

Interleukin-2 and histamine in combination inhibit tumour growth and angiogenesis in malignant glioma

Similar Documents

Interleukin-2 and histamine in combination inhibit tumour growth and angiogenesis in malignant glioma

Growth of cultured human glioma tumour cells can be regulated with histamine and histamine antagonists.

Alloimmune cells consume interleukin-2 and competitively inhibit the anti-tumour effects of interleukin-2.

Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour–stroma interaction

Alloimmune cells consume interleukin-2 and competitively inhibit the anti-tumour effects of interleukin-2

Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma

Tumour cell products inhibit both functional and immunoreactive interleukin 2 production by human blood lymphocytes.

Nitrosoureas Inhibit the Stathmin Mediated Migration and Invasion of Malignant Glioma Cells

Histamine Formation and Tumour Growth

Interleukin-2 and histamine in combination inhibit tumour growth and angiogenesis in malignant glioma